Vaccines
19 November 2019
Enrollment and Randomization of 12,463 Participants Complete in BiondVax’s Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial18 November 2019
Valneva Reports Excellent Final Phase 1 Results for its Chikungunya Vaccine Candidate, Confirms Plans14 November 2019
VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection12 November 2019
NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines12 November 2019
Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union11 November 2019
OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi®9 November 2019
Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting7 November 2019
Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure6 November 2019
Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment6 November 2019
Inovio demonstrates 80% 6-month progression-free survival in Phase 2 glioblastoma multiforme (GBM) study5 November 2019
FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older29 October 2019
Themis Bioscience and CEPI Announce Initiation of Phase 1 Clinical Trial with Lassa Fever Vaccine29 October 2019
GSK candidate vaccine demonstrates sustained level of protection against active pulmonary tuberculosis29 October 2019
RhoVac Receives Approval in Finland to Start Clinical Phase IIb Study in Prostate Cancer23 October 2019
BlueWillow Receives FDA Clearance to Begin Phase 1 Study of its Intranasal Anthrax Vaccine18 October 2019
Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease17 October 2019
Stallergenes Greer and Anergis Initiate New Study to Predict Efficacy of Second-Generation Allergen Immunotherapy15 October 2019
Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults8 October 2019
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial of Equine Encephalitis Virus VaccineNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports